siRNA targeting casitas B cell lymphoma-B (CBL-B)
US7595389B2 · kind B2 · utility
51Cited by
10References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 23, 2007 |
| Grant date | Sep 29, 2009 |
| Priority date | — |
| Expiry date | Oct 20, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CBL-B.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.